CORT

SEC source: 0001193125-26-414688 · ownership.xml · derivative · entry 5

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 133,334

Underlying: Common Stock · 8,333 shares

Expires 2034-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.

SEC source: 0001193125-26-414688 · ownership.xml · nonDerivative · entry 4

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,946

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction.

F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.24 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414688 · ownership.xml · nonDerivative · entry 3

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,093

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.16 to $116.04 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414688 · ownership.xml · nonDerivative · entry 2

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,179

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the Reporting Person being appointed an officer of the Issuer, which was in effect at the time of this transaction.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.03 to $114.90 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414688 · ownership.xml · nonDerivative · entry 1

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,279

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414684 · ownership.xml · derivative · entry 9

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,167

Underlying: Common Stock · 5,833 shares

Expires 2032-02-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-414684 · ownership.xml · derivative · entry 8

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,357 shares

Expires 2030-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-414684 · ownership.xml · nonDerivative · entry 6

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,683

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.

F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.25 to $116.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414684 · ownership.xml · nonDerivative · entry 5

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,427

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $116.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414684 · ownership.xml · nonDerivative · entry 4

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,873

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414684 · ownership.xml · nonDerivative · entry 3

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,040

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414674 · ownership.xml · derivative · entry 12

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,986

Underlying: Common Stock · 24,587 shares

Expires 2027-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-414674 · ownership.xml · nonDerivative · entry 5

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,938

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.39 to $117.22 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414674 · ownership.xml · nonDerivative · entry 4

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,682

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.38 to $116.36 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414674 · ownership.xml · nonDerivative · entry 3

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,525

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414684 · ownership.xml · derivative · entry 7

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,357

Underlying: Common Stock · 810 shares

Expires 2030-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-414684 · ownership.xml · nonDerivative · entry 2

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,683

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.23 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414684 · ownership.xml · nonDerivative · entry 1

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,493

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414674 · ownership.xml · derivative · entry 11

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,573

Underlying: Common Stock · 413 shares

Expires 2027-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-414674 · ownership.xml · nonDerivative · entry 2

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,938

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.30 to $115.615 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414674 · ownership.xml · nonDerivative · entry 1

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,351

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 150 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-414667 · ownership.xml · derivative · entry 1

Gunn Justin Frederick · CIK 0002155454 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2036-10-01

F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of October 1, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.

SEC source: 0001193125-26-405402 · ownership.xml · nonDerivative · entry 3

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Custodial Account for Child

Disclosed balance after: 20,571

F3 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

SEC source: 0001193125-26-405402 · ownership.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Custodial Account for Child

Disclosed balance after: 20,571

F2 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

SEC source: 0001193125-26-405402 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,056

F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 164 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-395827 · ownership.xml · derivative · entry 5

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,507

Underlying: Common Stock · 17,493 shares

Expires 2027-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-395827 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,156

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 164 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-393124 · ownership.xml · nonDerivative · entry 3

WILSON JAMES N · CIK 0001236387 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust

Disclosed balance after: 1,064,543

F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.70 to $111.705 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F5 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001193125-26-393124 · ownership.xml · nonDerivative · entry 2

WILSON JAMES N · CIK 0001236387 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust

Disclosed balance after: 1,067,343

F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.665 to $111.095 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F5 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001193125-26-393124 · ownership.xml · nonDerivative · entry 1

WILSON JAMES N · CIK 0001236387 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust

Disclosed balance after: 1,067,743

F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $109.66 to $110.64 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F5 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001193125-26-393125 · ownership.xml · derivative · entry 6

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,167

Underlying: Common Stock · 7,404 shares

Expires 2030-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-393125 · ownership.xml · derivative · entry 5

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,596 shares

Expires 2029-02-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-393125 · ownership.xml · nonDerivative · entry 4

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,683

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.92 to $114.50 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-393125 · ownership.xml · nonDerivative · entry 3

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,871

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 10, 2026 in effect at the time of this transaction.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.81 to $113.72 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-393125 · ownership.xml · nonDerivative · entry 2

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,683

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-393125 · ownership.xml · nonDerivative · entry 1

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,279

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 130 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382474 · ownership.xml · nonDerivative · entry 7

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,938

F9 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

F10 · price: The closing price on September 1, 2026 was used to calculate the withholding obligation.

F11 · balance_after: Includes 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382463 · ownership.xml · nonDerivative · entry 3

Mokari Atabak · CIK 0001678419 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,304

F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

F6 · price: The closing price on September 1, 2026 was used to calculate the withholding obligation.

F7 · balance_after: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382457 · ownership.xml · nonDerivative · entry 3

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,663

F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

F6 · price: The closing price on September 1, 2026 was used to calculate the withholding obligation.

F7 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382456 · ownership.xml · derivative · entry 12

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 141,667

Underlying: Common Stock · 58,333 shares

Expires 2034-02-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F16 · derivative.exercise_date: Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.

SEC source: 0001193125-26-382456 · ownership.xml · nonDerivative · entry 11

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,242

F8 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.

F15 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.255 to $115.57 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F7 · balance_after: Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382456 · ownership.xml · nonDerivative · entry 10

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,467

F8 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.

F14 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.24 to $115.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F7 · balance_after: Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382456 · ownership.xml · nonDerivative · entry 9

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,088

F8 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.

F13 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.11 to $114.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F7 · balance_after: Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382456 · ownership.xml · nonDerivative · entry 8

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,694

F8 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.

F12 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.08 to $113.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F7 · balance_after: Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382456 · ownership.xml · nonDerivative · entry 7

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,668

F8 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.

F11 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.06 to $111.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F7 · balance_after: Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382456 · ownership.xml · nonDerivative · entry 6

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,205

F8 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.

F10 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.06 to $111.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F7 · balance_after: Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382456 · ownership.xml · nonDerivative · entry 5

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,975

F8 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.

F9 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $108.97 to $109.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F7 · balance_after: Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382456 · ownership.xml · nonDerivative · entry 4

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,575

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · balance_after: Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382456 · ownership.xml · nonDerivative · entry 3

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,242

F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

F6 · price: The closing price on September 1, 2026 was used to calculate the withholding obligation.

F7 · balance_after: Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382450 · ownership.xml · nonDerivative · entry 3

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,683

F5 · kind: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

F6 · price: The closing price on September 1, 2026 was used to calculate the withholding obligation.

F7 · balance_after: Includes 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.